Experimental Drug Targets Cognitive Impairment in Schizophrenia

Encenicline (Forum Pharmaceuticals), a novel α-7 nicotinic acetylcholine receptor partial agonist, shows improvement of cognitive impairment in schizophrenia in a phase 2 randomized, controlled trial, potentially ushering in a long-anticipated treatment for an aspect of the disease not addressed by antipsychotics.

Although cognitive impairment occurs in nearly all (98%) patients with schizophrenia, antipsychotics do not adequately offer improvement.

With its unique mechanism seen as potentially helping to improve memory and cognitive function, encenicline is being studied as an adjunct to antipsychotics in treating cognitive impairment in schizophrenia as well as Alzheimer’s disease.

READ FULL ARTICLE Curated publisher From Med Scape